Susquehanna Fundamental Investments’s Atara Biotherapeutics ATRA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$131K	Buy	+566	New	+$180K	﹤0.01%	1428
2021 Q4	–	Sell	-436	Closed	-$195K	–	1427
2021 Q3	$195K	Sell	436 -127	-23%	-$45.5K	﹤0.01%	1542
2021 Q2	$219K	Sell	563 -1,224	-68%	-$437K	﹤0.01%	1459
2021 Q1	$642K	Buy	1,787 +1,241	+227%	+$549K	0.01%	1062
2020 Q4	$268K	Buy	546 +146	+37%	+$67.4K	﹤0.01%	1283
2020 Q3	$130K	Hold	400	–	–	﹤0.01%	1253
2020 Q2	$146K	Buy	+400	New	+$101K	0.01%	872

Other funds holding ATRA

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Susquehanna Fundamental Investments's ATRA Position: Q1 2022 in Review

Susquehanna Fundamental Investments opened a new position in Atara Biotherapeutics (ATRA) in Q1 2022: 566 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #1428 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in ATRA as recently as Q3 2021.

Susquehanna Fundamental Investments first reported a position in ATRA in Q2 2020 and has held it in 7 quarters since. The position peaked at $642K in Q1 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

Susquehanna Fundamental Investments held 566 shares of Atara Biotherapeutics worth $131K as of Q1 2022.
Atara Biotherapeutics was a new Susquehanna Fundamental Investments position in Q1 2022.
Atara Biotherapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1428 holding.
Susquehanna Fundamental Investments first reported a position in Atara Biotherapeutics in Q2 2020 and has held it in 7 quarters since.
Susquehanna Fundamental Investments's Atara Biotherapeutics position peaked at $642K in Q1 2021.
144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.